Dong Yumeng, Xu Tiangang, Xiao Guozheng, Hu Ziyan, Chen Jingyu
College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China.
Suzhou U-Synbio Co., Ltd., Suzhou, China.
Front Bioeng Biotechnol. 2022 Aug 10;10:909591. doi: 10.3389/fbioe.2022.909591. eCollection 2022.
Inflammatory bowel disease (IBD) is a complex, chronic intestinal inflammatory disorder that primarily includes Crohn's disease (CD) and ulcerative colitis (UC). Although traditional antibiotics and immunosuppressants are known as the most effective and commonly used treatments, some limitations may be expected, such as limited efficacy in a small number of patients and gut flora disruption. A great many research studies have been done with respect to the etiology of IBD, while the composition of the gut microbiota is suggested as one of the most influential factors. Along with the development of synthetic biology and the continuing clarification of IBD etiology, broader prospects for novel approaches to IBD therapy could be obtained. This study presents an overview of the currently existing treatment options and possible therapeutic targets at the preclinical stage with respect to microbial synthesis technology in biological therapy. This study is highly correlated to the following topics: microbiota-derived metabolites, microRNAs, cell therapy, calreticulin, live biotherapeutic products (LBP), fecal microbiota transplantation (FMT), bacteriophages, engineered bacteria, and their functional secreted synthetic products for IBD medical implementation. Considering microorganisms as the main therapeutic component, as a result, the related clinical trial stability, effectiveness, and safety analysis may be the major challenges for upcoming research. This article strives to provide pharmaceutical researchers and developers with the most up-to-date information for adjuvant medicinal therapies based on synthetic biology.
炎症性肠病（IBD）是一种复杂的慢性肠道炎症性疾病，主要包括克罗恩病（CD）和溃疡性结肠炎（UC）。尽管传统抗生素和免疫抑制剂是已知最有效且常用的治疗方法，但仍可能存在一些局限性，例如对少数患者疗效有限以及破坏肠道菌群。关于IBD的病因已经进行了大量研究，而肠道微生物群的组成被认为是最具影响力的因素之一。随着合成生物学的发展以及IBD病因的不断明确，IBD治疗新方法有望获得更广阔的前景。本研究概述了生物治疗中微生物合成技术在临床前阶段现有的治疗选择和可能的治疗靶点。本研究与以下主题高度相关：微生物群衍生代谢物、微小RNA、细胞治疗、钙网蛋白、活体生物治疗产品（LBP）、粪便微生物群移植（FMT）、噬菌体、工程菌及其用于IBD医学应用的功能性分泌合成产物。因此，将微生物作为主要治疗成分，相关临床试验的稳定性、有效性和安全性分析可能是未来研究的主要挑战。本文致力于为药物研究人员和开发人员提供基于合成生物学的辅助药物治疗的最新信息。
